Learn About Myelodysplastic Syndrome

What is the definition of Myelodysplastic Syndrome?

Myelodysplastic syndrome is a group of disorders when the blood cells produced in the bone marrow do not mature into healthy cells. This leaves you with fewer healthy blood cells in your body. The blood cells that have matured may not function properly.

Myelodysplastic syndrome (MDS) is a form of cancer. In about a third of people, MDS may develop into acute myeloid leukemia.

Save information for later
Sign Up
What are the alternative names for Myelodysplastic Syndrome?

Myeloid malignancy; Myelodysplastic syndrome; MDS; Preleukemia; Smoldering leukemia; Refractory anemia; Refractory cytopenia

What are the causes of Myelodysplastic Syndrome?

Stem cells in bone marrow form different types of blood cells. With MDS, the DNA in stem cells becomes damaged. Because the DNA is damaged, the stem cells can’t produce healthy blood cells.

The exact cause of MDS is not known. For most cases, there is no known cause.

Risk factors for MDS include:

  • Certain genetic disorders
  • Exposure to environmental or industrial chemicals, fertilizers, pesticides, solvents, or heavy metals
  • Smoking

Prior cancer treatment increases the risk for MDS. This is called secondary or treatment-related MDS.

  • Certain chemotherapy drugs increase the chance of developing MDS. This is a major risk factor.
  • Radiation therapy, when used with chemotherapy, increases the risk for MDS even more.
  • People who have stem cell transplants may develop MDS because they also receive high doses of chemotherapy.

MDS usually occurs in adults age of 60 years and older. It is more common in men.

What are the symptoms of Myelodysplastic Syndrome?

Early stage MDS often has no symptoms. MDS is often discovered during other blood tests.

People with very low blood counts often experience symptoms. Symptoms depend on the type of blood cell affected, and they include:

  • Weakness or tiredness due to anemia
  • Shortness of breath
  • Easy bruising and bleeding
  • Small red or purple pinpoint dots under the skin caused by bleeding
  • Frequent infections and fever
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Myelodysplastic Syndrome?

Your treatment will depend on several factors:

  • Whether you are low-risk or high-risk
  • The type of MDS you have
  • Your age, health, and other conditions you may have, such as diabetes or heart disease

The goal of MDS treatment is to prevent problems due to a shortage of blood cells, infections and bleeding. It may consist of:

  • Blood transfusion
  • Drugs that promote the production of blood cells
  • Drugs that suppress the immune system
  • Low-dose chemotherapy to improve blood cell counts
  • Stem cell transplantation

Your provider may try one or more treatments to see what your MDS responds to.

Who are the top Myelodysplastic Syndrome Local Doctors?
Elite
Highly rated in
32
conditions
Oncology
Hematology Oncology
Hematology

University Of Texas MD Anderson Cancer Center

Houston, TX 

Tapan Kadia is an Oncologist and a Hematologist Oncology doctor in Houston, Texas. Dr. Kadia has been practicing medicine for over 21 years and is rated as an Elite doctor by MediFind in the treatment of Myelodysplastic Syndrome. He is also highly rated in 32 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia, Myelodysplastic Syndrome, Leukemia, and Acute Lymphoblastic Leukemia. He is board certified in Internal Medicine, Hematology, and Medical Oncology and licensed to treat patients in Texas. Dr. Kadia is currently accepting new patients.

Elite
Highly rated in
27
conditions
Hematology Oncology
Hematology

Moffitt Cancer Center

Tampa, FL 

Jeffrey Lancet is a Hematologist Oncology specialist and a Hematologist in Tampa, Florida. Dr. Lancet has been practicing medicine for over 30 years and is rated as an Elite doctor by MediFind in the treatment of Myelodysplastic Syndrome. He is also highly rated in 27 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia, Myelodysplastic Syndrome, Leukemia, and Acute Myeloblastic Leukemia with Maturation. He is board certified in Hematology/oncology and licensed to treat patients in Florida. Dr. Lancet is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn more
Elite
Highly rated in
23
conditions
Oncology

Memorial Sloan Kettering Monmouth

Middletown, NJ 

Virginia Klimek is an Oncologist in Middletown, New Jersey. Dr. Klimek has been practicing medicine for over 28 years and is rated as an Elite doctor by MediFind in the treatment of Myelodysplastic Syndrome. She is also highly rated in 23 other conditions, according to our data. Her top areas of expertise are Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Myeloblastic Leukemia without Maturation, and Acute Myeloblastic Leukemia with Maturation. She is board certified in Medical Oncology and licensed to treat patients in New York. Dr. Klimek is currently accepting new patients.

What is the outlook (prognosis) for Myelodysplastic Syndrome?

The outlook will depend on your type of MDS and severity of symptoms. Your overall health also may affect your chances of recovery. Many people have stable MDS that does not progress into cancer for years, if ever.

Some people with MDS may develop acute myeloid leukemia (AML).

What are the possible complications of Myelodysplastic Syndrome?

MDS complications include:

  • Bleeding
  • Infections such as pneumonia, gastrointestinal infections, urinary infections
  • Acute myeloid leukemia
When should I contact a medical professional for Myelodysplastic Syndrome?

Contact your provider if you:

  • Feel weak and tired most of the time
  • Bruise or bleed easily, have bleeding of the gums or frequent nosebleeds
  • You notice red or purple spots of bleeding under the skin
Bone marrow aspiration
What are the latest Myelodysplastic Syndrome Clinical Trials?
Monitoring Risks for Hematological Changes in Gas Station Workers
Match to trials
Find the right clinical trials for you in under a minute
Get started
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
What are the Latest Advances for Myelodysplastic Syndrome?
Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with de novo acute myeloid leukemia and high-risk myelodysplastic syndrome aged over 70 years.
Successful management of severe allergic reactions to platelet transfusion with omalizumab: A case report.
Tired of the same old research?
Check Latest Advances
Low Dose Splenic Irradiation as Adjunct Therapy for Patients With High Level of Anti-Human Leukocyte Antigen Donor-Specific Antibodies (Anti-HLA DSAs) Prior to Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-HSCT).
What are our references for Myelodysplastic Syndrome?

Hasserjian RP, Head DR. Myelodysplastic syndromes. In: Jaffe ES, Arber DA, Campo E, Harris NL, Quintanilla-Martinez L, eds. Hematopathology. 2nd ed. Philadelphia PA: Elsevier; 2017:chap 45.

National Cancer Institute website. Myelodysplastic/myeloproliferative neoplasms treatment (PDQ) - health professional version. www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq. Updated February 1, 2019. Accessed December 17, 2019.

Steensma DP, Stone RM. Myelodysplastic syndromes. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 172.